Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Core Viewpoint - Psyence Biomedical Ltd. has decided to postpone the effective date of its previously announced reverse stock split of its common stock, which was initially set for January 20, 2026 [1][2]. Group 1: Reverse Stock Split Details - The Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to take effect at the market opening on January 20, 2026 [2]. - The Company will issue a subsequent press release and file required notifications with Nasdaq before establishing a new effective date for the reverse stock split [3]. - Until a new effective date is set, the Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "PBM" and its current CUSIP [3]. Group 2: Company Overview - Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics [4]. - It is the first life sciences biotechnology company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq [4]. - The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for various mental health disorders [4].